Back to top
more

Guardant Health (GH)

(Delayed Data from NSDQ)

$168.52 USD

168.52
1,517,526

-2.40 (-1.40%)

Updated Aug 27, 2026 04:00 PM ET

After-Market: $169.00 +0.48 (0.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (GH) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Guardant Health (GH) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Guardant Health (GH) closed at $70.96, marking a +0.45% move from the previous day.

Zacks Equity Research

Guardant Health (GH) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

During Guardant Health's (GH) Q3 conference call, investors will watch out for the latest news on the colorectal cancer screening rates of its LUNAR-2 blood test.

Zacks Equity Research

Has Guardant Health (GH) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (GH) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (GH) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Exact Sciences Gets FDA Nod for Label Expansion of Cologuard

by Zacks Equity Research

Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

Tirthankar Chakraborty headshot

3 Cancer Treatment Stocks to Enrich Your Portfolio

by Tirthankar Chakraborty

Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.

Zacks Equity Research

AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut

by Zacks Equity Research

AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.

Zacks Equity Research

Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.